Tamoxifen Market

Market Insights

Breast cancer is the most common form of cancer found in women across the globe. Although the incidence of breast cancer has decreased in the past few years, reducing the mortality rate even further remains a big concern. Tamoxifen reduces the effects of the estrogen hormone in the human body. The drug is used to treat/prevent breast cancer for both women and men. Tamoxifen can also be used to cure other kinds of cancers. Tamoxifen is also used to reduce the risk of breast cancer in women with a high risk of developing breast cancer.

Geographically, the intraoperative imaging market is studied for the following regional markets:

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • France
  • The U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa
• Rest of the World

Market size and forecast for these regional and country-level markets are presented in this study for 2013-2022. In addition, market growth rates for the forecast period 2016-2022 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and prospects. Information such as major market events, key breast cancer statistics, drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global tamoxifen market. In addition, tools such as market positioning of key players and attractive investment propositions provide the readers with insights into the competitive scenario of the global clinical nutrition market. This report concludes with a company profiles section that highlights major information about the key players engaged in the tamoxifen market.

For this study, the global tamoxifen market is categorized as follows:

North America was the largest regional market for tamoxifen drugs in 2015 and accounted for over 35%. High incidence of breast cancer, awareness about screening, prevention, and management of breast cancer, and favorable government policies are the prime factors allowing the growth of the tamoxifen market in North America. The region is expected to retain its lead through the forecast period, followed by Europe. The trends in the European market are majorly determined by U.K., Germany, France, and Belgium. Belgium is among the countries with the highest incidence of breast cancer, and this market the country a promising market for tamoxifen drugs. U.K. and Germany are currently the largest country-level markets in Europe. Furthermore, Asia-Pacific and the Rest of the World are estimated to register the fastest market growth during the forecast period due to the growing recurrence of breast cancer and the high prevalence of late-stage breast cancer detection. In addition, the rapid development of healthcare infrastructure is also for growth in these markets.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary

Chapter 3 Tamoxifen: Market Dynamics and Outlook
3.1 Introduction
3.2 Breast Cancer: Key Statistics
3.3 Major Events Assessment
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Advantages of Hormone Therapy Across Different Stages of Treatment
3.4.1.2 Widespread use as Adjuvant and Neo-Adjuvant Therapy
3.4.2 Challenges
3.4.2.1 Growth in Tamoxifen-Resistant Breast Cancer
3.4.3 Opportunities
3.4.3.1 Alternative uses of Tamoxifen
3.5 Attractive Investment Proposition
3.6 Market Positioning of Key Manufacturers

Chapter 4 Global Tamoxifen Market, Pipeline Analysis
4.1 Preface
4.2 Phase III
4.3 Phase II
4.4 Phase I

Chapter 5 Global Tamoxifen Market, by Geography
5.1 Introduction
5.2 North America
5.2.1 U.S.
5.2.2 Canada
5.3 Europe
5.3.1 United Kingdom
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia-Pacific
5.5 Rest of the World

Chapter 6 Company Profiles
6.1 Astra Zeneca plc
6.1.1 Astra Zeneca plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.2 Teva Pharmaceutical Industries Ltd.
6.2.1 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.3 Allergen plc
6.3.1 Allergen plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.4 Mylan Pharmaceuticals, Inc.
6.4.1 Mylan Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
6.5 Apotex, Inc
6.5.1 Apotex, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)

List of Figures

FIG. 1 Global Tamoxifen Market: Research Methodology
FIG. 2 Global Tamoxifen Market, by Geography, 2015 (US$ Mn)
FIG. 3 Attractive Investment Proposition: Global Tamoxifen Market, by Geography, 2015
FIG. 4 Market Positioning of Key Manufacturers in Tamoxifen Market, 2015 (Value %)
FIG. 5 U.S. Tamoxifen Market, 2013 – 2022 (US$ Mn)
FIG. 6 Canada Tamoxifen Market, 2013 – 2022 (US$ Mn)
FIG. 7 European Age-Standardized Mortality Rates per 100,000 Population, Females, U.K.
FIG. 8 United Kingdom Tamoxifen Market, 2013 – 2022, (US$ Mn)
FIG. 9 Germany Tamoxifen Market, 2013 – 2022, (US$ Mn)
FIG. 10 Rest of Europe Tamoxifen Market, 2013 – 2022, (US$ Mn)
FIG. 11 China Tamoxifen Market Revenue, 2015 – 2022 (US$ Mn)
FIG. 12 Japan Tamoxifen Market, 2013– 2022 (US$ Mn)
FIG. 13 Rest of Asia-Pacific Tamoxifen Market, 2013 – 2022 (US$ Mn)

List of Tables

TABLE 1 Global Tamoxifen Market Revenue, 2015 Vs 2022 (US$ Mn)
TABLE 2 National Statistics: Breast Cancer Incidence Rate for Key Countries, 2012
TABLE 3 North America Tamoxifen Market, by Country, 2013-2022 (US$ Mn)
TABLE 4 Estimated New Female Breast Cancer Cases and Deaths by Age, U.S., 2013
TABLE 5 Canada Breast Cancer Statistics, 2015
TABLE 6 Europe Tamoxifen Market, 2013–2022, (US$ Mn)
TABLE 7 Breast Cancer Incidence Rate and Mortality Rate in Germany, 2012
TABLE 8 Breast Cancer Incidence Rate in Rest of European Countries, 2012
TABLE 9 Breast Cancer Survivors Post Diagnosis in Rest of European Countries, 2012
TABLE 10 Asia-Pacific Tamoxifen Market, 2013-2022 (US$ Mn)
TABLE 11 Rest of the World Tamoxifen Market, by Region, 2013-2022
TABLE 12 Astra Zeneca plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 14 Allergen plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 15 Mylan Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 16 Apotex, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)